SCHEMBL2415143

SCHEMBL2415143

Cc1cc(-c2ccc(C(F)(F)F)cc2)nnc1N(C)CCc1csc(SC(C)(C)C(=O)O)n1

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 4/20 0.39
POLB P06746 1/20 0.37
SLC22A12 Q96S37 3/20 0.36
TP53 P04637 5/20 0.36
ALDH1A1 P00352 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PPARD Q03181 4/20 0.34
LMNA P02545 3/20 0.34
PPARG P37231 2/20 0.33
MAPT P10636 2/20 0.33
SCN9A Q15858 1/20 0.33
MCHR1 Q99705 1/20 0.33
KDM4E B2RXH2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GSTO1 P78417 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2415719 0.90 PPARA (0.40) PPARAPOLBSLC22A12TP53L3MBTL1
SCHEMBL2418667 0.86 SLC22A12 (0.42) PPARAPOLBSLC22A12TP53ALDH1A1
SCHEMBL2412439 0.83 SLC22A12 (0.40) PPARAPOLBSLC22A12TP53ALDH1A1
SCHEMBL2408257 0.82 POLB (0.43) PPARAPOLBSLC22A12TP53LMNA
SCHEMBL12273012 0.80 SLC22A12 (0.41) PPARAPOLBSLC22A12TP53ALDH1A1
SCHEMBL12274122 0.80 SLC22A12 (0.43) PPARAPOLBSLC22A12TP53L3MBTL1
Hydrochloric Acid SCHEMBL2419940 0.79 SLC22A12 (0.42) PPARAPOLBSLC22A12TP53L3MBTL1
Hydrochloric Acid SCHEMBL2414916 0.79 SLC22A12 (0.40) PPARAPOLBSLC22A12TP53LMNA
SCHEMBL12273073 0.77 SLC22A12 (0.40) PPARAPOLBSLC22A12TP53LMNA
Hydrochloric Acid SCHEMBL2410530 0.76 SLC22A12 (0.39) PPARAPOLBSLC22A12TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PPARA 1/4885POLB 3392/4885SLC22A12 920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.